Capricor Therapeutics Inc (NASDAQ:CAPR) has a beta value of 4.58 and has seen 1.23 million shares traded in the last trading session. The company, currently valued at $572.01M, closed the last trade at $12.58 per share which meant it gained $0.24 on the day or 1.94% during that session. The CAPR stock price is -86.01% off its 52-week high price of $23.40 and 72.02% above the 52-week low of $3.52.
The consensus among analysts is that Capricor Therapeutics Inc (CAPR) is Buy stock at the moment, with a recommendation rating of 1.00. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 3 have rated it as a Hold, with 3 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -0.09.
Capricor Therapeutics Inc (NASDAQ:CAPR) trade information
Sporting 1.94% in the green in last session, the stock has traded in the red over the last five days, with the highest price hit on recent trading when the CAPR stock price touched $12.58 or saw a rise of 11.28%. Year-to-date, Capricor Therapeutics Inc shares have moved -8.84%, while the 5-day performance has seen it change -8.18%. Over the past 30 days, the shares of Capricor Therapeutics Inc (NASDAQ:CAPR) have changed -10.72%.
Wall Street analysts have a consensus price target for the stock at $15, which means that the shares’ value could jump 16.13% from current levels. The projected low price target is $10.0 while the price target rests at a high of $21.5. In that case, then, we find that the current price level is -70.91% off the targeted high while a plunge would see the stock lose 20.51% from current levels.
Capricor Therapeutics Inc (CAPR) estimates and forecasts
The company’s shares have gained 208.33% over the past 6 months. Revenue growth from the last financial year stood is estimated to be -16.70%.
7 analysts offering their estimates for the company have set an average revenue estimate of 9.87M for the current quarter. 3 have an estimated revenue figure of 5.5M for the next ending quarter. Year-ago sales stood 12.09M and 4.91M respectively for this quarter and the next, and analysts expect sales will shrink by -18.35% for the current quarter and -16.70% for the next.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 30.59% over the past 5 years.
CAPR Dividends
Capricor Therapeutics Inc is expected to release its next earnings report in April this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Capricor Therapeutics Inc (NASDAQ:CAPR)’s Major holders
The top two institutional holders are BLACKROCK INC. with over 1.63 million shares worth more than $7.77 million. As of 2024-06-30, BLACKROCK INC. held 5.194% of shares outstanding.
The other major institutional holder is VANGUARD GROUP INC, with the holding of over 1.55 million shares as of 2024-06-30. The firm’s total holdings are worth over $7.39 million and represent 4.9401% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF and Vanguard Total Stock Market Index Fund . As of Dec 31, 2024 , the former fund manager holds about 3.16% shares in the company for having 1.44 shares of worth $18.1 million while later fund manager owns 1.13 shares of worth $14.25 million as of Dec 31, 2024 , which makes it owner of about 2.49% of company’s outstanding stock.
